BioNTech SE Net Cash Flow 2019-2025 | BNTX

BioNTech SE net cash flow for the twelve months ending June 30, 2025 was $-3.278B, a 53.89% decline year-over-year.

  • BioNTech SE annual net cash flow for 2024 was $-2.058B, a 14.02% decline from 2023.
  • BioNTech SE annual net cash flow for 2023 was $-2.393B, a 118.65% decline from 2022.
  • BioNTech SE annual net cash flow for 2022 was $12.835B, a 2148.48% increase from 2021.

BioNTech SE Net Cash Flow 2019-2025 | BNTX

  • BioNTech SE annual net cash flow for 2024 was $-2.058B, a 14.02% decline from 2023.
  • BioNTech SE annual net cash flow for 2023 was $-2.393B, a 118.65% decline from 2022.
  • BioNTech SE annual net cash flow for 2022 was $12.835B, a 2148.48% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.1B
Amgen (AMGN)$155.3B
Gilead Sciences (GILD)$141.6B
Vertex Pharmaceuticals (VRTX)$99.7B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.7B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$60.7B
Alnylam Pharmaceuticals (ALNY)$58.2B
Argenex SE (ARGX)$41.5B
Insmed (INSM)$27.1B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.2B
Genmab (GMAB)$15.6B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.6B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Guardant Health (GH)$7.7B